Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus Pembrolizumab in Advanced or Metastatic Hepatocellular Carcinoma After PD-1/PD-L1 Inhibitors
2020-003555-16Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and regorafenib in hepatocellular carcinoma (HCC), sponsored by Bayer. Primary endpoint: Objective response rate. Started Oct 2020; status: completed.
02
Drugs
pembrolizumabregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2020-003555-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003555-16.